BioSpace News Archive

Promontory Therapeutics Inc. will present a poster on its clinical trial in progress of PT-112, its lead therapeutic candidate, in patients with late-stage metastatic castration-resistant prostate cancer, to be held at the American Society of Clinical Oncology 2023 Genitourinary Cancers (ASCO GU) Symposium. ASCO GU will take place in San Francisco and online on Feb. 16-18, 2023.

Kyocera Corporation (President: Hideo Tanimoto) today announced it has developed a new “contactless intelligent millimeter-wave sensing system”.

CoImmune, Inc. today announced that preclinical models show CAR T cells engineered with OrexiCAR technology to secrete a CD47-SIRPα checkpoint blocker have improved anti-tumor activity and reverse myeloid immunosuppression in tumors.

Flare Therapeutics today announced that management will present a company overview at the upcoming Guggenheim Healthcare Talks 2023 Oncology Day on Thursday, February 9, 2023 at 2:45 p.m. ET in New York, NY.

Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the publication of a study in Scientific Reports, a journal in the Nature portfolio, validating the use of SeptiCyte® RAPID as a triaging tool for COVID-19 patients requiring hospitalization and potentially ICU care.

Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 (‘4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb in August 2021, has entered Phase 1 clinical trials in the United States.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2022 on Thursday, February 23, 2023, before the U.S. financial markets open.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper in Pediatric Nephrology, which highlights the clinical utility of Renasight™ in aiding the diagnosis and management of kidney disease.

AC Immune to Present at the SVB Securities Global Biopharma Conference Lausanne, Switzerland, February 2, 2023.

Babson Diagnostics, a science-first, health care technology company, today announced BetterWay™ Blood Testing, the name of its new diagnostic blood testing service that is designed around the most important element of testing – the customer.